Skip to main content
SpringerLink
Log in

Comparison of cyproterone acetate plus ethinyl estradiol and finasteride in the treatment of hirsutism

  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

The aim of this study was to compare the clinical efficacy and safety of low dose cyproterone acetate-estrogen combination (Diane®) and the 5α-reductase inhibitor finasteride in the treatment of hirsutism. Fourty-two women with hirsutism were included in the study. Twenty-one patients treated with cyproterone acetate (CPA) 2 mg and ethinyl estradiol (E) 35 µg daily on days 5–25 of the menstrual cycle, 21 with finasteride 5 mg daily. Hirsutism score, hormone levels, multiscreen blood chemistry and side effects were evaluated at three-monthly intervals for 9 months. A significant decrease in hirsutism score as compared to baseline was observed after 9 months with either CPA+E (Diane®) (mean ± SE, 15.81±1.19 i 8.38±1.21) or finasteride treatment (17.81±1.05 vs 10.86±0.91) (p<0.0005). The reductions in hirsutism scores (mean% ± SE) were 14.23 ± 2.29 vs 19.77±2.22 (p<0.05) at 3, 40.23±4.58 vs 29.49±2.69 (p<0.02) at 6 and 50.99±4.13 vs 39.87±3.30 (p<0.02) at 9 months in CPA+E and finasteride groups, respectively. No significant changes were observed in hormone levels during finasteride treatment. Serum free testosterone significantly decreased at the third month of treatment, and remained suppressed for the duration of treatment in CPA+E group. DHEAS levels also decreased significantly after 6 and 9 months of therapy with CPA+E. SHBG significantly increased during CPA+E treatment. We conclude that both drugs are effective and well tolerated, but CPA+E appears to be more effective than 5α-reductase inhibitor finasteride in long-term treatment of hirsute women. Diane® is also a cost-effective drug.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Barbieri R.L. Hyperandrogenic disorders. Clin. Obstet. Gynecol. 33: 640, 1990.

    Article  PubMed  CAS  Google Scholar 

  2. Rittmaster R.S. Medical treatment of androgen-dependent hirsutism. J. Clin. Endocrinol. Metab. 80: 2559, 1995.

    PubMed  CAS  Google Scholar 

  3. Neumann F. Pharmacology and potential use of cyproterone acetate. Horm. Metab. 59: 903, 1977.

    Google Scholar 

  4. Schriock E.A., Schriock E.D. Treatment of hirsutism. Clin. Obstet Gynecol. 34: 852, 1991.

    Article  PubMed  CAS  Google Scholar 

  5. Sudduth S.L., Koronkowski M.J. Finasteride: the first 5 alpha-reductase inhibitor. Pharmacotherapy 13: 309, 1993.

    PubMed  CAS  Google Scholar 

  6. Rittmaster R S. Finasteride. N. Eng. J. Med. 330: 120, 1994.

    Article  CAS  Google Scholar 

  7. Fruzetti F., Lorenzo D., Parrini D., Ricci C. Effects of finasteride, a 5α-reductase inhibitor, on circulating androgens and gonadotropin secretion in hirsute women. J. Clin. Endocrinol. Metab. 79: 831, 1994.

    Google Scholar 

  8. Moghetti P., Castello R., Magnani C.M., Tosi F., Negri C., Armanini D., Bellotti G., Muggeo M. Clinical and hormonal effects of the 5α-reductase inhibitor finasteride in idiopathic hirsutism. J. Clin. Endocrinol. Metab. 79: 1115, 1994.

    PubMed  CAS  Google Scholar 

  9. Hatch R., Rosenfield R., Kim M.H., Tredway D. Hirsutism: implications, etiology, and management. Am. J. Obstet. Gynecol. 140: 815, 1981.

    PubMed  CAS  Google Scholar 

  10. Hammerstein J., Meckies J., Leo-Rossberg J. Use of cyproterone acetate (CPA) in the treatment of acne, hirsutism and virilism. J. Steroid Biochem. 6: 827, 1975.

    Article  PubMed  CAS  Google Scholar 

  11. Tremblay R.R. Treatment of hirsutism with spironolactone. J. Clin. Endocrinol. Metab. 15: 363, 1986.

    Article  CAS  Google Scholar 

  12. Müderris I., Bayram F., Şahin Y., Keleştimur F., Tutuş A., Ayata D. The efficacy of 250 mg/day flutamide in the treatment of patients with hirsutism. Fertil. Steril. 66: 220, 1996.

    PubMed  Google Scholar 

  13. Belisle S., Love E.J. Clinical efficacy and safety of cyproterone acetate in severe hirsutism: result of a multycentred Canadian study. Fertil. Steril. 46: 1015, 1986.

    PubMed  CAS  Google Scholar 

  14. Barth J.H., Cherry C.A., Wojnarowska F., Dawber R.P.R. Cyproterone acetate for severe hirsutism: results of a double-blind dose ranging study. Clin. Endocrinol. (Oxf.) 35: 5, 1991.

    Article  CAS  Google Scholar 

  15. Serafini P., Ablan F., Lobo R.A. 5α-reductase activity in the genital skin of hirsute women. J. Clin. Endocrinol. Metab. 60: 349, 1985.

    Article  PubMed  CAS  Google Scholar 

  16. Wong I.A., Morris R.S., Chang L., Spahn M.-A., Stanczyk F.Z., Lobo R.A. A prospective randomized trial comparing finasteride to spironolactone in the treatment of hirsute women. J. Clin. Endocrinol. Metab. 80: 233, 1995.

    PubMed  CAS  Google Scholar 

  17. Ciotta L., Cianci A., Calogero A.E., Palumbo M.A., Marietta E., Sciuto A., Palumbo G. Clinical and endocrine effects of finasteride, 5α-re-ductase inhibitor, in women with idiopathic hirsutism. Fertil. Steril. 64: 299, 1995.

    PubMed  CAS  Google Scholar 

  18. Castello R., Tosi F., Perrone F., Negri C., Muggeo M., Moghetti P. Outcome of long-term treatment with the 5α-reductase inhibitor finasteride in idiopathic hirsutism: clinical and hormonal effects during a 1-year cours of therapy and 1-year follow-up. Fertil. Steril. 66: 734, 1996.

    PubMed  CAS  Google Scholar 

  19. Neumann F. Pharmacology and potential use of cyproterone acetate Horm. Metab. 59: 903, 1977.

    Google Scholar 

  20. Girard J., Baumann K.B., Buchler U., Zuppinger K., Haas H.G., Staup J.J., Wyss H.I. Cyproterone acetate and ACTH adrenal function. J. Clin. Endocrinol. Metab. 47: 581, 1978.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, Erciyes University, Faculty of Medicine, 38039, Kayseri, Turkey

    Y. Şahin M.D. & I. Müderris

  2. Departments of Endocrinology, Erciyes University, Faculty of Medicine, Kayseri, Turkey

    F. Bayram & F. Keleştimur

Authors
  1. Y. Şahin M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F. Bayram
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F. Keleştimur
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. I. Müderris
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Şahin, Y., Bayram, F., Keleştimur, F. et al. Comparison of cyproterone acetate plus ethinyl estradiol and finasteride in the treatment of hirsutism. J Endocrinol Invest 21, 348–352 (1998). https://doi.org/10.1007/BF03350769

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03350769

Key-words

Search

Navigation